The pharma will pay $800 million for the biotech, which was launched nearly two decades ago by Alnylam and Ionis to advance ...

My husband got a call in the middle of the night while I was in an induced coma to prepare ... I was given a lifesaving drug to treat a possible rare disease — one of the 5% of rare diseases ...

Comprehensive overview of lupus in India, symptoms, treatment, and challenges faced in diagnosis and management.

Orphan drug specialist Amicus Therapeutics is paying Dimerix $30 million cash for U.S. rights to the phase 3 prospect DMX-200 ...

Novartis has committed another $1.7 billion to its ambition to become a kidney disease leader. The Swiss drugmaker is making ...

KEY HIGHLIGHTS First patient expected to start therapy by end of Q2-2025 in Phase 2a proof-of concept clinical trial for ...